Emanuele D'Amico
Emanuele D'Amico is an expert in Neurology at University of Foggia (Italy). As of October 2026, ScienceLeadR ranks Emanuele D'Amico in the top 1% of experts worldwide for Autoimmune Diseases and Multiple Sclerosis. Emanuele D'Amico has authored 184 publications, the most recent in 2026, and is an investigator in 7 clinical trials, 5 of them ongoing. SLR score: 716 (community average: 125). How the SLR is computed.
LeadR Profile
Neurology
Subspecialties: Public Health - Pharmacy - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2012 - 2026
Number : 184
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study). PMID 42400474 — registries, sclerosis, multiple sclerosis, safety, incidence, central nervous system diseases, neoplasms, drug therapy, drug-related side effects and adverse reactions, antibodies, monoclonal, therapeutics, infections | Mult Scler | 2026 | 0 |
| Global, Regional, and National Burden of Heart Failure, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023. PMID 42814432 — heart diseases, heart failure, heart, cardiovascular diseases, public health, global burden of disease, prevalence, cost of illness, chagas disease | JAMA Cardiol | 2026 | 0 |
| Measuring the composition and availability of human resources for health by sex in 204 countries and territories, 1990-2023, and workforce gaps for universal health coverage: a systematic analysis for the Global Burden of Disease Study 2023. PMID 42612647 — nurses, health workforce, pharmacists, public health, global burden of disease, dentists, sex, occupations, cost of illness, retention, psychology, workforce | Lancet Public Health | 2026 | 1 |
| AI-based predictive biomarkers for chronic neurological diseases: the rAIdD prospective, multicenter, observational study protocol. PMID 42539597 — dementia, life style, neuroimaging, biomarkers, machine learning, wearable electronic devices, risk factors, diagnosis, ethics committees, artificial intelligence, digital biomarkers | Front Neurol | 2026 | 1 |
| Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023. PMID 42525403 — myocardial ischemia, heart diseases, cholesterol, ldl, growth, ischemic stroke, stroke, heart, aging, uncertainty, global burden of disease, cost of illness, therapeutics, demography | JAMA Top journal | 2026 | 6 |
Clinical Studies 7
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 10
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study of an On Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis 2025-523726-40-00 — injections, sclerosis, multiple sclerosis, safety, multiple chronic conditions | Phase 3 | Recruiting | 2026 |
| A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis 2025-521546-23-00 — sclerosis, multiple sclerosis, safety, secondary progressive multiple sclerosis | Phase 3 | Recruiting | 2026 |
| Non inferiority study of frexalimab subcutaneous administration compared to intravenous administration in adult participants with multiple sclerosis 2024-519304-28-00 — sclerosis, multiple sclerosis, safety, administration, intravenous, pharmacokinetics | Phase 3 | Recruiting | 2026 |
| A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis 2024-517980-22-00 — sclerosis, multiple sclerosis, therapeutic equivalency | Phase 2 | Active not recruiting | 2025 |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis NCT06141473 — sclerosis, multiple sclerosis, safety, tablets, solutions, cholestyramine resin, therapeutics, male | Phase 3 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map